Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: An under-recognized complication of prolonged treatment for ovarian cancer

Kidney International

Volumn 85, Issue 1, 2014, Pages 213-

  Shavit, Linda ^a   Lifschitz, Meyer D ^a   Gabizon, Alberto ^a   Kwa, Maryann ^b   Muggia, Franco ^b   Slotki, Itzchak ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; DOXORUBICIN; LIPOSOME;

CANCER CONTROL; CHRONIC KIDNEY DISEASE; DRUG FORMULATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ENCAPSULATION; HUMAN; HYPERTENSION; KIDNEY INJURY; KIDNEY THROMBOSIS MICROANGIOPATHY; LETTER; LONG TERM CARE; MICROANGIOPATHY; NEPHROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; PROTEINURIA;

ANTINEOPLASTIC AGENTS; GLOMERULONEPHRITIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY GLOMERULUS; NEOPLASMS; PARANEOPLASTIC SYNDROMES;

EID: 84891513106     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.408     Document Type: Letter

References (4)

1. Jhaveri KD, Shah HH, Calderon K et al. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int 2013; 84: 34-44.
2. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-993. (Pubitemid 27106281)
3. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42: 419-436. (Pubitemid 36649037)
4. Kwa M, Baumgartner R, Shavit L et al. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist 2012; 17: 1534-1540.